These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 34309113)

  • 21. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Golgi phosphoprotein 3 promotes ovarian cancer progression and is associated with cisplatin resistance.
    Liu T; Jin ZW; Li Y; Zhang G; Yang XY; Xu XM; Ma YC
    J Cancer Res Ther; 2022 Apr; 18(2):488-495. PubMed ID: 35645119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
    Elsayed AM; Bayraktar E; Amero P; Salama SA; Abdelaziz AH; Ismail RS; Zhang X; Ivan C; Sood AK; Lopez-Berestein G; Rodriguez-Aguayo C
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33668685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation on the mechanism of the combination of eremias multiocellata and cisplatin in reducing chemoresistance of gastric cancer based on
    Cheng FE; Li Z; Bai X; Jing Y; Zhang J; Shi X; Li T; Li W
    Aging (Albany NY); 2024 Feb; 16(4):3386-3403. PubMed ID: 38345573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [IL-17A/lL-17RA reduces cisplatin sensitivity of ovarian cancer SKOV3 cells by regulating autophagy].
    Wang L; Zhang X; Wang L; Wang B; Zhang J; Li Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Nov; 40(11):1550-1556. PubMed ID: 33243748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyanidin-3-O-glucoside and cisplatin inhibit proliferation and downregulate the PI3K/AKT/mTOR pathway in cervical cancer cells.
    Li X; Zhao J; Yan T; Mu J; Lin Y; Chen J; Deng H; Meng X
    J Food Sci; 2021 Jun; 86(6):2700-2712. PubMed ID: 33908630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNA 1301 inhibits cisplatin resistance in human ovarian cancer cells by regulating EMT and autophagy.
    Yu JL; Gao X
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1688-1696. PubMed ID: 32141535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myeloid differentiation factor 88 promotes cisplatin chemoresistance in ovarian cancer.
    Liu G; Du P; Zhang Z
    Cell Biochem Biophys; 2015 Mar; 71(2):963-9. PubMed ID: 25308861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
    Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
    Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Inhibition of GRP78 expression reverses cisplatin resistance in human ovarian cancer].
    Fan LM; Su J; Dong H; Wei M; Cui MH
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(17):1341-4. PubMed ID: 24029486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSAT1 Upregulation Contributes to Cell Growth and Cisplatin Resistance in Cervical Cancer Cells via Regulating PI3K/AKT Signaling Pathway.
    Duan W; Liu X
    Ann Clin Lab Sci; 2020 Jul; 50(4):512-518. PubMed ID: 32826249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Icariin enhances the chemosensitivity of cisplatin‑resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
    Jiang S; Chang H; Deng S; Fan D
    Int J Oncol; 2019 Jun; 54(6):1933-1942. PubMed ID: 31081049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ethoxysanguinarine directly targets CIP2A to inhibit proliferation and induce autophagy of SGC7901/DDP cells].
    Wan F; Tan M; Xiang YC; Liu XW; Peng P; Liu Y
    Zhongguo Zhong Yao Za Zhi; 2022 Nov; 47(21):5890-5899. PubMed ID: 36472008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endoplasmic reticulum stress regulates proliferation, migration and invasion of human ovarian cancer SKOV3 cells through PI3K/AKT/mTOR signaling pathway.
    Yang N; Qu YJ; Cheng Y; Liang T; Zhang MN; Zhang D; Dong LN; Wang XW; Zhang GM
    Cancer Biomark; 2017 Jul; 19(3):263-269. PubMed ID: 28453460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway.
    Li B; Yang J; Lu Z; Liu B; Liu F
    J BUON; 2019; 24(2):739-745. PubMed ID: 31128031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
    Zou W; Ma X; Hua W; Chen B; Cai G
    Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TRIAP1 Inhibition Activates the Cytochrome c/Apaf-1/Caspase-9 Signaling Pathway to Enhance Human Ovarian Cancer Sensitivity to Cisplatin.
    Zhang TM
    Chemotherapy; 2019; 64(3):119-128. PubMed ID: 31661694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MiR-100 up-regulation enhanced cell autophagy and apoptosis induced by cisplatin in osteosarcoma by targeting mTOR.
    Yu Z; Li N; Jiang K; Zhang N; Yao LL
    Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5867-5873. PubMed ID: 30280766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.